IP Library Granted Patent US 8,227,597
Granted Patent B2
US 8,227,597 · App. 11/864,016 · Granted Jul 24, 2012

Quinolone carboxylic acids, derivatives thereof, and methods of making and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,597
App. No.
11/864,016
Granted
Jul 24, 2012
Kind
B2
Abstract

A process of preparing a quinolone carboxylic acid or its derivatives having Formula I, Ia, or IV, as shown herein, comprises using a starting quinolone that already has one or more desired substituents at one or more particular positions on the quinolone ring and preserving the orientation of such substituents throughout the synthesis. The present process comprises fewer steps than prior-art processes. The present process also can include a simple separation of a desired enantiomer of the quinolone carboxylic acid or its derivatives from the enantiomeric mixture. Pharmaceutical compositions comprising fluoroquinolones prepared by the present process can be used effectively against a variety of microbial pathogens.

Claims (23)

1. A process of preparing a fluoroquinolone having Formula I or salts thereof, the process comprising contacting a first compound having Formula II with a second compound having Formula III to produce a fluoroquinolone having Formula I, wherein the fluoroquinolone, the first compound, and the second compound are represented by

wherein R 1 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, and substituted C 5 -C 24 heteroaryl groups; R 2 is selected from the group consisting of unsubstituted amino group, and amino groups substituted with one or two lower alkyl groups; R 3 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted lower alkoxy groups, substituted lower alkoxy groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, unsubstituted C 5 -C 24 aryloxy groups, substituted C 5 -C 24 aryloxy groups, unsubstituted C 5 -C 24 heteroaryloxy groups, and substituted C 5 -C 24 heteroaryloxy groups; X is selected from the group consisting of halogen atoms; Y is selected from the group consisting of CH 2 , O, S, SO, SO 2 , and NR 4 , wherein R 4 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, and cycloalkyl groups; and Z is selected from the group consisting of oxygen and two hydrogen atoms.

2. The process of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 6 -C 14 substituted and unsubstituted aryl groups, and C 5 -C 14 substituted and unsubstituted heteroaryl groups; R 2 is selected from the group consisting of unsubstituted amino group and amino groups substituted with one or two C 1 -C 5 alkyl groups; R 3 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 1 -C 5 substituted and unsubstituted alkoxy groups, C 5 -C 14 substituted and unsubstituted aryl groups, C 5 -C 14 substituted and unsubstituted heteroaryl groups, and C 5 -C 14 substituted and unsubstituted aryloxy groups; and X is selected from the group consisting of Cl, F, and Br.

3. The process of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, and C 1 -C 5 substituted and unsubstituted alkyl groups; R 2 is selected from the group consisting of unsubstituted amino group and amino groups substituted with one or two C 1 -C 5 alkyl groups; R 3 is selected from the group consisting of C 3 -C 10 cycloalkyl groups; X is selected from the group consisting of Cl and F; Y comprises hydrogen; and Z is two hydrogen atoms.

4. The process of claim 1 , wherein the step of contacting is carried out at a temperature in a range from about room temperature to about 100° C.

5. The process of claim 3 , wherein the step of contacting is carried out at a temperature in a range from about room temperature to about 100° C.

6. The process of claim 1 , wherein the step of contacting the first compound having Formula II with the second compound having Formula III results in a crude product comprising an enantiomeric mixture of a fluoroquinolone having Formula I, and the process further comprises washing or dissolving the crude product with water to produce an aqueous mixture, and substantially recovering an enantiomer from the aqueous mixture.

7. The process of claim 6 , wherein the step of recovering the enantiomer from the aqueous mixture is carried out by recrystallization.

8. A process of preparing a fluoroquinolone having Formula IV or salts thereof, the method comprising:

(a) contacting a first compound having Formula II with a third compound having Formula V to produce a fourth compound having Formula VI, wherein the fluoroquinolone having Formula IV, the first compound, the third compound, and the fourth compound are represented by

 wherein R 1 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, and substituted C 5 -C 24 heteroaryl groups; R 3 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted lower alkoxy groups, substituted lower alkoxy groups, unsubstituted C 5 - C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, unsubstituted C 5 -C 24 aryloxy groups, substituted C 5 -C 24 aryloxy groups, unsubstituted C 5 -C 24 heteroaryloxy groups, and substituted C 5 -C 24 heteroaryloxy groups; X is selected from the group consisting of halogen atoms; Y is selected from the group consisting of CH 2 , O, S, SO, SO 2 , and NR 4 , wherein R 4 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, and cycloalkyl groups; Z is selected from the group consisting of oxygen and two hydrogen atoms; and R 5 is a protected amino group having a formula of —NR 6 , wherein R 6 is a protecting group that is capable of leaving the protected amino group —NR 6 and is selected from the group consisting of nitrophenylalkylidene, t-Boc, and Fmoc group; and

(b) contacting the fourth compound with a sufficient amount of a catalyst and at a temperature in the range from room temperature to 100° C. to effect a cleavage of the protecting group R 6 from the —NR 6 group, to produce a fluoroquinolone having Formula IV, wherein said catalyst is an acid when R 6 is the nitrophenylalkylidene group, and said catalyst is a base when R 6 is the t-Boc or F-moc group.

9. The process of claim 8 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 6 -C 14 substituted and unsubstituted aryl groups, and C 6 -C 14 substituted and unsubstituted heteroaryl groups; R 3 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 1 -C 5 substituted and unsubstituted alkoxy groups, C 5 -C 14 substituted and unsubstituted aryl groups, C 5 -C 14 substituted and unsubstituted heteroaryl groups, and C 5 -C 14 substituted and unsubstituted aryloxy groups; and X is selected from the group consisting of Cl, F, and Br.

10. The process of claim 8 , wherein R 1 is selected from the group consisting of hydrogen, and C 1 -C 5 substituted and unsubstituted alkyl groups; R 3 is selected from the group consisting of C 3 -C 10 cycloalkyl groups; R 6 is the nitrophenylalkylidene group; X is selected from the group consisting of Cl and F; Y comprises hydrogen; and Z is two hydrogen atoms.

11. The process of claim 10 , wherein the catalyst is hydrochloric acid.

12. The process of claim 8 , wherein the step of contacting the fourth compound with a catalyst produces a crude product comprising an enantiomeric mixture of the fluoroquinolone having Formula IV, and the process further comprises washing or dissolving the crude product with water to produce an aqueous mixture, and substantially recovering an enantiomer from the aqueous mixture.

13. The process of claim 12 , wherein the step of recovering the enantiomer from the aqueous mixture is carried out by recrystallization.

14. A process for preparing a fluoroquinolone carboxylic acid having Formula Ia or salts thereof, the process comprising:

(a) contacting a compound having Formula IIa with a compound having Formula VIIa at a temperature in the range from about room temperature to about 100° C. for a time from about 10 minutes to about 7 days, to produce a compound having Formula VIa, wherein the fluoroquinolone having Formula Ia and the compounds having Formulae IIa, VIa, and VIIa are represented by the following, wherein X is Cl and R 3 is cyclopropyl

(b) contacting the compound having Formula VIa with an amount of HCl equal to about 0.1 to about 5 moles per mole of the compound having Formula VIIa at a temperature in the range from about room temperature to about 100° C., in a presence of methanol, to produce the fluoroquinolone carboxylic acid having Formula Ia; and

(c) recovering the fluoroquinolone carboxylic acid having Formula Ia.

15. The process of claim 14 , wherein the step of contacting the compound having Formula VIa with HCl produces a crude product comprising an enantiomeric mixture of the fluoroquinolone having Formula Ia, and the process further comprises washing or dissolving the crude product with water to produce an aqueous mixture, and substantially recovering an enantiomer from the aqueous mixture.

16. The process of claim 15 , wherein the step of substantially recovering the enantiomer from the aqueous mixture is carried out by recrystallization.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 15, 2012
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028788/0271 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2007
From: HARMS, ARTHUR E.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 019896/0322 →